Utilizing the T12 skeletal muscle index on computed tomography images for sarcopenia diagnosis in lung cancer patients
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This approach can facilitate the non-invasive identification of Sc without extra imaging procedures, supporting personalized risk stratification and treatment planning [8,10,14]”
From AI-Assistance Body Composition CT at T12 and T4 in Lung Cancer: Diagnosing Sarcopenia, and Its Correlation with Morphofunctional Assessment Techniques (2025) · cites this paper as [8]
In the citing paper
“Numerous studies have identified Sc as an independent risk factor for worse postoperative outcomes, reduced tolerance to therapy, and decreased survival in LC patients [4,5,6,7,8].”
From AI-Assistance Body Composition CT at T12 and T4 in Lung Cancer: Diagnosing Sarcopenia, and Its Correlation with Morphofunctional Assessment Techniques (2025) · cites this paper as [8]
In the citing paper
“CT stands out as the gold standard for muscle mass evaluation, typically performed at the third lumbar vertebra (L3).”
From AI-Assistance Body Composition CT at T12 and T4 in Lung Cancer: Diagnosing Sarcopenia, and Its Correlation with Morphofunctional Assessment Techniques (2025) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Derstine, B. A., Holcombe, S. A., Ross, B. E., Wang, N. C., Su, G. L., & Wang, S. C. (2018) · Scientific Reports · doi:10.1038/s41598-018-29825-5 · Cited by 507 · cited 2×
“17 Ishida et al. 18 developed a formula predicting SMA at L3 using T12 CT, which demonstrated strong concordance and correlation (ICC ¼ 0.849; r ¼ 0.858).”
BackgroundMethodInfluentialPrevalence of sarcopenia in patients with solid tumors: A meta‐analysis based on 81,814 patients
Surov, A., & Wienke, A. (2022) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.2415 · Cited by 138
Research works printed but not linked: 25
- Falcon, 2017, Sarcopenia and the new ICD-10-CM code: screening, staging, and diagnosis considerations, Fed Pract, 34, 24
- Petermann-Rocha, 2022, Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis, J Cachexia Sarcopenia Muscle, 13, 86, 10.1002/jcsm.12783 · DOI · Paper page
- Bolte, 2022, Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy, Front Oncol, 12, 10.3389/fonc.2022.986236 · DOI
- Yamada, 2023, Clinical utility of psoas muscle volume in assessment of sarcopenia in patients with early-stage non-small cell lung cancer, J Cancer Res Clin Oncol, 149, 3277, 10.1007/s00432-022-04234-4 · DOI
- de Jong, 2022, The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients, J Cachexia Sarcopenia Muscle, 13, 1554, 10.1002/jcsm.12967 · DOI
- Jang, 2020, Skeletal muscle mass change during chemotherapy: a systematic review and meta-analysis, Anticancer Res, 40, 2409, 10.21873/anticanres.14210 · DOI
- Xia, 2020, Sarcopenia and adverse health-related outcomes: an umbrella review of meta-analyses of observational studies, Cancer Med, 9, 7964, 10.1002/cam4.3428 · DOI · Paper page
- Nagano, 2019, Rehabilitation nutrition for iatrogenic sarcopenia and sarcopenic dysphagia, J Nutr Health Aging, 23, 256, 10.1007/s12603-018-1150-1 · DOI
- Fearon, 2011, Definition and classification of cancer cachexia: an international consensus, Lancet Oncol, 12, 489, 10.1016/S1470-2045(10)70218-7 · DOI · Paper page
- Prado, 2008, Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study, Lancet Oncol, 9, 629, 10.1016/S1470-2045(08)70153-0 · DOI · Paper page
- Watanabe, 2023, Skeletal muscle area predicts the outcomes of non-small-cell lung cancer after trimodality therapy, Interdiscip Cardiovasc Thorac Surg, 36, 10.1093/icvts/ivad020 · DOI
- Wakefield, 2022, The association between thoracic sarcopenia and survival is gender specific in early-stage lung cancer, J Thorac Dis, 14, 4256, 10.21037/jtd-22-273 · DOI · Paper page
- Troschel, 2021, Sarcopenia on preoperative chest computed tomography predicts cancer-specific and all-cause mortality following pneumonectomy for lung cancer: a multicenter analysis, Cancer Med, 10, 6677, 10.1002/cam4.4207 · DOI
- Sun, 2020, Prognostic significance of low pectoralis muscle mass on preoperative chest computed tomography in localized non-small cell lung cancer after curative-intent surgery, Lung Cancer, 147, 71, 10.1016/j.lungcan.2020.07.008 · DOI
- Ishida, 2020, Formula for the cross-sectional area of the muscles of the third lumbar vertebra level from the twelfth thoracic vertebra level slice on computed tomography, Geriatrics (Basel)., 5
- Dong, 2020, Identifying sarcopenia in advanced non-small cell lung cancer patients using skeletal muscle CT radiomics and machine learning, Thorac Cancer, 11, 2650, 10.1111/1759-7714.13598 · DOI · Paper page
- Tan, 2021, Diagnosing sarcopenia and myosteatosis based on chest computed tomography images in healthy Chinese adults, Insights Imaging, 12, 163, 10.1186/s13244-021-01106-2 · DOI
- Li, 2022, Effects of protein supplementation and exercise on delaying sarcopenia in healthy older individuals in Asian and non-Asian countries: a systematic review and meta-analysis, Food Chem X, 13, 10.1016/j.fochx.2022.100210 · DOI
- G, 2021, Implications of race and ethnicity in sarcopenia US National Prevalence of Sarcopenia by muscle mass, strength, and function indices, Gerontol Geriatr Res, 4, 126
- Brennan-Olsen, 2020, Education, occupation and operational measures of sarcopenia: six years of Australian data, Australas J Ageing, 39, e498, 10.1111/ajag.12816 · DOI
- Takamori, 2018, Clinical impact and risk factors for skeletal muscle loss after complete resection of early non-small cell lung cancer, Ann Surg Oncol, 25, 1229, 10.1245/s10434-017-6328-y · DOI · Paper page
- Xu, 2023, Diagnosis of sarcopenia using the L3 skeletal muscle index estimated from the L1 skeletal muscle index on MR images in patients with cirrhosis, J Magn Reson Imag, 58, 1569, 10.1002/jmri.28690 · DOI
- Yang, 2021, Factors that improve chest computed tomography-defined sarcopenia prognosis in advanced non-small cell lung cancer, Front Oncol, 11
- Voulgaridou, 2024, Diagnostic criteria and measurement techniques of sarcopenia: a critical evaluation of the up-to-date evidence, Nutrients, 16, 436, 10.3390/nu16030436 · DOI
- Jang, 2020, Skeletal muscle mass loss during cancer treatment: differences by race and cancer site, Oncol Nurs Forum, 47, 557, 10.1188/20.ONF.557-566 · DOI
Cited by
Montero-Benitez, M. Z., Carmona-Llanos, A., Fernández-Jiménez, R., Román-Jobacho, A., Gómez-Millán, J., Modamio-Molina, J., Cabrera-Cesar, E., Vegas-Aguilar, I., Amaya-Campos, M. D. M., Tinahones, F. J., et al. (2025) · Cancers · doi:10.3390/cancers17193255 · Cited by 7
Vickers, A. J., McSweeney, D. M., Choudhury, A., Weaver, J., West, C., Kerns, S., Azria, D., Farcy-Jaquet, M.-P., Chang-Claude, J., Dunning, A., et al. (2026) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2026.111673
Metadata
- Authors
- He, S., Zhang, G., Huang, N., Chen, S., Ruan, L., Liu, X., & Zeng, Y.
- ORCID
- Zeng, Yingchun
- Venue
- Asia-Pacific Journal of Oncology Nursing
- Publisher
- Elsevier BV
- Published
- 2024-06
- Volume
- 11
- Issue
- 6
- Pages
- 100512
- ISSN
- 2347-5625
- Cited by
- 7
- References
- 3
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.